325 related articles for article (PubMed ID: 23738751)
1. Candidiasis drug discovery and development: new approaches targeting virulence for discovering and identifying new drugs.
Pierce CG; Lopez-Ribot JL
Expert Opin Drug Discov; 2013 Sep; 8(9):1117-26. PubMed ID: 23738751
[TBL] [Abstract][Full Text] [Related]
2. Development of Anti-Virulence Approaches for Candidiasis via a Novel Series of Small-Molecule Inhibitors of
Romo JA; Pierce CG; Chaturvedi AK; Lazzell AL; McHardy SF; Saville SP; Lopez-Ribot JL
mBio; 2017 Dec; 8(6):. PubMed ID: 29208749
[No Abstract] [Full Text] [Related]
3. Targeting Candida albicans filamentation for antifungal drug development.
Vila T; Romo JA; Pierce CG; McHardy SF; Saville SP; Lopez-Ribot JL
Virulence; 2017 Feb; 8(2):150-158. PubMed ID: 27268130
[TBL] [Abstract][Full Text] [Related]
4. Biofilm of Candida albicans: formation, regulation and resistance.
Pereira R; Dos Santos Fontenelle RO; de Brito EHS; de Morais SM
J Appl Microbiol; 2021 Jul; 131(1):11-22. PubMed ID: 33249681
[TBL] [Abstract][Full Text] [Related]
5. Potential Targets for Antifungal Drug Discovery Based on Growth and Virulence in Candida albicans.
Li X; Hou Y; Yue L; Liu S; Du J; Sun S
Antimicrob Agents Chemother; 2015 Oct; 59(10):5885-91. PubMed ID: 26195510
[TBL] [Abstract][Full Text] [Related]
6. Unraveling the anti-virulence potential and antifungal efficacy of 5-aminotetrazoles using the zebrafish model of disseminated candidiasis.
Radakovic N; Nikolić A; Jovanović NT; Stojković P; Stankovic N; Šolaja B; Opsenica I; Pavic A
Eur J Med Chem; 2022 Feb; 230():114137. PubMed ID: 35077918
[TBL] [Abstract][Full Text] [Related]
7. High-content phenotypic screenings to identify inhibitors of Candida albicans biofilm formation and filamentation.
Pierce CG; Saville SP; Lopez-Ribot JL
Pathog Dis; 2014 Apr; 70(3):423-31. PubMed ID: 24623598
[TBL] [Abstract][Full Text] [Related]
8. Synergistic combinations of antifungals and anti-virulence agents to fight against Candida albicans.
Cui J; Ren B; Tong Y; Dai H; Zhang L
Virulence; 2015; 6(4):362-71. PubMed ID: 26048362
[TBL] [Abstract][Full Text] [Related]
9.
Romo JA; Pierce CG; Esqueda M; Hung CY; Saville SP; Lopez-Ribot JL
Front Cell Infect Microbiol; 2018; 8():227. PubMed ID: 30042929
[TBL] [Abstract][Full Text] [Related]
10. Effect of silver nanoparticles on Candida albicans biofilms: an ultrastructural study.
Lara HH; Romero-Urbina DG; Pierce C; Lopez-Ribot JL; Arellano-Jiménez MJ; Jose-Yacaman M
J Nanobiotechnology; 2015 Dec; 13():91. PubMed ID: 26666378
[TBL] [Abstract][Full Text] [Related]
11. Repurposing Pilocarpine Hydrochloride for Treatment of Candida albicans Infections.
Nile C; Falleni M; Cirasola D; Alghamdi A; Anderson OF; Delaney C; Ramage G; Ottaviano E; Tosi D; Bulfamante G; Morace G; Borghi E
mSphere; 2019 Jan; 4(1):. PubMed ID: 30674648
[TBL] [Abstract][Full Text] [Related]
12. Virulence and biofilms as promising targets in developing antipathogenic drugs against candidiasis.
Ahmad Khan MS; Alshehrei F; Al-Ghamdi SB; Bamaga MA; Al-Thubiani AS; Alam MZ
Future Sci OA; 2020 Feb; 6(2):FSO440. PubMed ID: 32025329
[No Abstract] [Full Text] [Related]
13. Candida albicans biofilm chip (CaBChip) for high-throughput antifungal drug screening.
Srinivasan A; Lopez-Ribot JL; Ramasubramanian AK
J Vis Exp; 2012 Jul; (65):e3845. PubMed ID: 22847237
[TBL] [Abstract][Full Text] [Related]
14. Global Transcriptomic Analysis of the Candida albicans Response to Treatment with a Novel Inhibitor of Filamentation.
Romo JA; Zhang H; Cai H; Kadosh D; Koehler JR; Saville SP; Wang Y; Lopez-Ribot JL
mSphere; 2019 Sep; 4(5):. PubMed ID: 31511371
[TBL] [Abstract][Full Text] [Related]
15. Novel Sulfones with Antifungal Properties: Antifungal Activities and Interactions with Candida spp. Virulence Factors.
Gizińska M; Staniszewska M; Ochal Z
Mini Rev Med Chem; 2019; 19(1):12-21. PubMed ID: 30246638
[TBL] [Abstract][Full Text] [Related]
16. Thymus vulgaris essential oil and thymol inhibit biofilms and interact synergistically with antifungal drugs against drug resistant strains of Candida albicans and Candida tropicalis.
Jafri H; Ahmad I
J Mycol Med; 2020 Apr; 30(1):100911. PubMed ID: 32008964
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of antifungal resistance and developments in alternative strategies to combat Candida albicans infection.
Sharma K; Parmanu PK; Sharma M
Arch Microbiol; 2024 Feb; 206(3):95. PubMed ID: 38349529
[TBL] [Abstract][Full Text] [Related]
18. Utilization of an in vitro biofabricated 3D skin as a pathological model of cutaneous candidiasis.
Kitisin T; Muangkaew W; Ampawong S; Sukphopetch P
New Microbiol; 2020 Oct; 43(4):171-179. PubMed ID: 33021319
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis of Candida albicans biofilm.
Tsui C; Kong EF; Jabra-Rizk MA
Pathog Dis; 2016 Jun; 74(4):ftw018. PubMed ID: 26960943
[TBL] [Abstract][Full Text] [Related]
20. Antifungal activity of ribavirin used alone or in combination with fluconazole against Candida albicans is mediated by reduced virulence.
Zhang M; Yan H; Lu M; Wang D; Sun S
Int J Antimicrob Agents; 2020 Jan; 55(1):105804. PubMed ID: 31605727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
